| Entry |
|
|---|
| Name |
Xanomeline (USAN) |
|---|
| Formula |
C14H23N3OS
|
|---|
| Exact mass |
281.1562
|
|---|
| Mol weight |
281.4169
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Neuropsychiatric agent
DG01490 Muscarinic cholinergic receptor agonist
|
|---|
| Remark |
|
|---|
| Efficacy |
Dementia therapeutic agent, Muscarinic acetylcholine receptor agonist |
|---|
| Comment |
Alzheimer's disease treatment
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04080 | Neuroactive ligand-receptor interaction |
|
|---|
| Interaction |
|
|---|
| Structure map |
| map07220 | Cholinergic and anticholinergic drugs |
|
|---|
| Brite |
Drug groups [BR:br08330]
Neuropsychiatric agent
DG01490 Muscarinic cholinergic receptor agonist
DG01300 Xanomeline
D06330 Xanomeline
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Acetylcholine (muscarinic)
CHRM1
D06330 Xanomeline (USAN)
CHRM4
D06330 Xanomeline (USAN)
Drug groups [BR:br08330]
Neuropsychiatric agent
DG01490 Muscarinic cholinergic receptor agonist
DG01300 Xanomeline
|
|---|
| Other DBs |
|
|---|
| KCF data |
ATOM 19
1 N1y N 13.2218 -16.0130
2 C1x C 13.2218 -17.4120
3 C1x C 14.4333 -18.1115
4 C2x C 15.6449 -17.4120
5 C2y C 15.6449 -16.0130
6 C1x C 14.4333 -15.3136
7 C1a C 12.0102 -15.3136
8 C8y C 16.8751 -15.3026
9 C8y C 18.0123 -16.1056
10 N5x N 19.1238 -15.2729
11 S2x S 18.6753 -13.9585
12 N5x N 17.2867 -13.9789
13 O2a O 17.9612 -17.4810
14 C1b C 19.1587 -18.2331
15 C1b C 20.3945 -17.5795
16 C1b C 21.5891 -18.3302
17 C1b C 22.8504 -17.6636
18 C1b C 24.0654 -18.4265
19 C1a C 25.2866 -17.7812
BOND 20
1 1 2 1
2 2 3 1
3 3 4 1
4 4 5 2
5 5 6 1
6 1 6 1
7 1 7 1
8 5 8 1
9 8 9 1
10 9 10 2
11 10 11 1
12 11 12 1
13 8 12 2
14 9 13 1
15 13 14 1
16 14 15 1
17 15 16 1
18 16 17 1
19 17 18 1
20 18 19 1
|
|---|
